Cargando…

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

Detalles Bibliográficos
Autores principales:	Van Deun, Armand, Decroo, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167426/ https://www.ncbi.nlm.nih.gov/pubmed/34095546 http://dx.doi.org/10.1016/j.jctube.2021.100240

Ejemplares similares

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Gopie, F.A., et al.
Publicado: (2021)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Should treatment of low-level mono-resistant tuberculosis be different?
por: Gopie, F.A., et al.
Publicado: (2021)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
por: Van Deun, Armand, et al.
Publicado: (2022)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis
por: Meyssonnier, Vanina, et al.
Publicado: (2014)

Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru
por: Villegas, Leonela, et al.
Publicado: (2016)

Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control
por: Malenfant, Jason H, et al.
Publicado: (2021)

Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique
por: Gonzaga, Lorena D. M., et al.
Publicado: (2021)

Management of rifampicin mono‐resistant tuberculosis in Queensland, Australia: a retrospective case series
por: Gibson, Justine, et al.
Publicado: (2018)

Primary Extrapulmonary Rifampicin Mono-Resistant Tuberculosis of the Parotid Gland in an Indian Female: The World’s First Case
por: Yadav, Sankalp
Publicado: (2022)

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
por: Habimana, Dominique Savio, et al.
Publicado: (2021)

Person‐centred care and short oral treatment for rifampicin‐resistant tuberculosis improve retention in care in Kandahar, Afghanistan
por: Mesic, Anita, et al.
Publicado: (2022)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya
por: Aricha, S. A., et al.
Publicado: (2019)

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance
por: Torrea, Gabriela, et al.
Publicado: (2019)

Primary Extrapulmonary Rifampicin Mono-Resistant Tuberculosis of the Knee in an Indian Female Without Pulmonary Involvement: The World's First Case
por: Yadav, Sankalp
Publicado: (2023)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2019)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes
por: Katende, Bulemba, et al.
Publicado: (2020)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests
por: Ardizzoni, E., et al.
Publicado: (2021)

Primary Rifampicin Mono-Resistant Extrapulmonary Tuberculosis of the Knee Without Pulmonary Involvement: One of the First Cases of Its Type in an Immunocompetent Male
por: Yadav, Sankalp
Publicado: (2023)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Rifampicin Resistance in Tuberculosis Outbreak, London, England
por: Jenkins, Claire, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4vaet7td8bop324rr2s3ffl7sj